Bjorn Knollmann
Fellowship Program Director · Vanderbilt University Medical Center
Credentials: · · ·
History
- Present
Vanderbilt University Medical Center Fellowship
- Present
Vanderbilt University Medical Center · Vanderbilt Univ Sch of Med
Present
Until 1998
Research
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans
Nature Medicine · 2009 · Last of 10 authors · 447 citations
Journal of Clinical Investigation · 2006 · First of 15 authors · Corresponding · 384 citations
Circulation Research · 2017 · Last of 12 authors · Corresponding · 315 citations
26 papers
- NC
13 papers · 12 as a fellow
12 papers
11 papers · 11 as a resident
- JS
10 papers · 6 as a fellow
8 papers
6 papers
6 papers
Grants
- 2026–2030
Therapeutic Development of RyR2-Inhibiting Flecainide Analogs for Arrhythmia Prevention
National Heart, Lung, and Blood Institute · R01
Contact PI · $856.7K · Vanderbilt University Medical Center
- 2026–2028
Therapeutic Development of the RyR2-Inhibitor Ent-Verticilide for Atrial Fibrillation
National Heart, Lung, and Blood Institute · R01
Contact PI · $1.7M · Vanderbilt University Medical Center
- 1977–2027
Clinical Pharmacology Training Program
National Institute of General Medical Sciences · T32
Contact PI · $5M · Vanderbilt University Medical Center
- 2019–2026
Toward a Mechanism-Based Approach to Treating Cardiac Arrhythmia
National Heart, Lung, and Blood Institute · R35
Contact PI · $7.1M · Vanderbilt University Medical Center
Clinical trials
- 2016–2020
New Formulations of Propafenone to Treat Atrial Fibrillation
Principal investigator · Terminated · Phase 1, Phase 2
Vanderbilt University